![Recombinant Adeno-Associated Virus (rAAV) Technology Pioneered by AskBio’s Dr. Jude Samulski is Key Component of All FDA Approved AAV Gene Therapeutics](https://dailytalks.org/wp-content/uploads/2023/01/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics.jpg)
Research Triangle Park, N.C. (December 20, 2022) – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA’s approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder…
Read More